STOCK TITAN

Ionis Pharmaceuticals (NASDAQ: IONS) director Ludwig Hantson files initial Form 3

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC director Ludwig Hantson filed an initial Form 3, which is a mandatory statement of beneficial ownership for insiders. This filing establishes his status as a director-level insider of the company but does not report any stock transactions or specific holdings.

Positive

  • None.

Negative

  • None.
Form 3 regulatory
"filed an initial Form 3, which is a mandatory statement of beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"an initial Form 3, which is a mandatory statement of beneficial ownership for insiders"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"register his insider status with the SEC rather than to disclose any trading activity"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Ludwig Hantson’s Form 3 filing for IONS mean?

The Form 3 shows Ludwig Hantson has become an insider of Ionis Pharmaceuticals as a director. It is an initial beneficial ownership report and, in this case, does not list any specific stock transactions or derivative positions.

Does the IONS Form 3 for Ludwig Hantson show any share purchases or sales?

No, the Form 3 for Ludwig Hantson reports zero buy, sell, acquire, or dispose transactions. It serves only to register his insider status with the SEC rather than to disclose any trading activity in Ionis Pharmaceuticals stock.

Are there any option exercises or derivative positions in the IONS Form 3?

The filing reports zero derivative transactions and an empty derivative summary. This means no option exercises, conversions, or other derivative activities are disclosed for Ludwig Hantson in this initial ownership statement for Ionis Pharmaceuticals.

Does the Form 3 indicate large holdings or changes for IONS stock?

The summarized data show no reported holdings entries or trading changes in this Form 3. It is purely an initial registration of Ludwig Hantson as a reporting person and does not quantify his share or option positions in Ionis Pharmaceuticals.

Is there any indication of gifts, tax withholding, or restructurings in the IONS Form 3?

The transaction summary lists zero gifts, tax-withholding dispositions, or restructuring transactions. This confirms the filing is administrative, recording insider status for Ludwig Hantson without any accompanying transfers or adjustments involving Ionis Pharmaceuticals securities.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
HANTSON LUDWIG

(Last)(First)(Middle)
2855 GAZELLE COURT

(Street)
CARLSBAD CALIFORNIA 92010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2026
3. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
By: Patrick R. O'Neil, attorney-in-fact For: Ludwig Hantson06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)